Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...
In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing ...
Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade ...
Blood transfusions are essential for patients with cancer, sickle cell disease, and traumatic injuries, but blood supply ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
The United States’ official exit from the World Health Organization (WHO) is set to be finalized today, Thursday January 22, ...
Pharmaceutical Executive: What was Daiichi Sankyo's strategy for preparing for the JP Morgan Healthcare Conference? Ken ...
Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...
Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results